A Single-arm, Open-label Phase IIa Study to Evaluate the Efficacy and Safety of Copanlisib Monotherapy in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL), Who Failed Ibrutinib Treatment or Were Unable to Tolerate Ibrutinib
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2017
At a glance
- Drugs Copanlisib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Bayer
- 17 Jan 2017 Status changed from completed to discontinued.
- 05 Dec 2016 Status changed from recruiting to completed.
- 29 Apr 2016 Planned number of patients changed from 12 to 15.